Stephen Biggar
Chairman at ACADIA PHARMACEUTICALS INC.
Net worth: - $ as of 2024-03-30
Profile
Dr. Stephen R. Biggar is an Independent Director at TScan Therapeutics, Inc., an Independent Director at Kiniksa Pharmaceuticals Ltd. and a Chairman at ACADIA Pharmaceuticals, Inc. He is on the Board of Directors at TScan Therapeutics, Inc., Kiniksa Pharmaceuticals Ltd. and Vivelix Pharmaceuticals, Ltd. Dr. Biggar was previously employed as an Independent Director by Synageva BioPharma Corp. and a Partner by Baker Bros. Advisors LP. He also served on the board at BioCryst Pharmaceuticals, Inc. and Synageva BioPharma Corp. /Old/. He received his undergraduate degree from the University of Rochester, a graduate degree from Stanford University and a doctorate degree from Stanford University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-03-30 | 0 ( -.--% ) | - $ | 2024-03-30 | |
2023-05-23 | 0 ( -.--% ) | - $ | 2024-03-30 |
Stephen Biggar active positions
Companies | Position | Start |
---|---|---|
ACADIA PHARMACEUTICALS INC. | Chairman | 2016-06-09 |
KINIKSA PHARMACEUTICALS, LTD. | Director/Board Member | 2015-09-30 |
TSCAN THERAPEUTICS, INC. | Director/Board Member | 2021-02-28 |
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Former positions of Stephen Biggar
Companies | Position | End |
---|---|---|
SYNAGEVA BIOPHARMA CORP | Director/Board Member | 2015-06-21 |
Synageva BioPharma Corp. /Old/
Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Director/Board Member | 2011-11-03 |
BIOCRYST PHARMACEUTICALS, INC. | Director/Board Member | 2011-10-09 |
Vivelix Pharmaceuticals, Ltd.
Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Director/Board Member | - |
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Portfolio Manager-Equities | - |
Training of Stephen Biggar
Rochester Christian University | Undergraduate Degree |
Stanford University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
ACADIA PHARMACEUTICALS INC. | Health Technology |
TSCAN THERAPEUTICS, INC. | Health Technology |
Private companies | 6 |
---|---|
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Finance |
Synageva BioPharma Corp. /Old/
Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Kiniksa Pharmaceuticals Ltd. | |
Vivelix Pharmaceuticals, Ltd.
Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Health Technology |
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Health Technology |
- Stock Market
- Insiders
- Stephen Biggar